 Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate riskreward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. Pre-revenue biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isnt like following the rest of the market, either. In many cases, biotech earnings reports arent a lightning rod for share-price movements. Instead, these stocks tend to ebb and flow on clinical data releases and regulatory approval decisions, which are arguably far more important metrics for gauging biotechnology firms long-term prospects.So, how are investors supposed to distinguish between the long-term winners and those poised to take an L? We suggest taking a page from the analyst communitys playbook.Using TipRanks database, we were able to scan the densely populated industry for the most compelling plays. These biotech stocks not only have earned overwhelmingly bullish support from the Wall Street analysts who cover them, but sky-high upside based on the pros estimates. Here are seven of Wall Streets best biotech stocks right now, according to the analyst community, which believes each of these picks has triple-digit return potential. SEE ALSO: Pros Picks: The 15 Best Nasdaq Stocks You Can Buy 